Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AK104 + bevacizumab + paclitaxel + cisplatin or carboplatin
- Development stage
- Unknown
- Lead developer
- Akeso
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
AK104 + bevacizumab + paclitaxel + cisplatin or carboplatin is a combination regimen used primarily for the first-line treatment of persistent, recurrent, or metastatic cervical cancer. **AK104**, also known as cadonilimab, is a bispecific monoclonal antibody targeting both PD-1 and CTLA-4 to enhance anti-tumor immune responses. **Bevacizumab** is a monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A) to inhibit angiogenesis. **Paclitaxel** is a microtubule inhibitor that disrupts cell division, and **cisplatin or carboplatin** are platinum-based chemotherapeutic agents with DNA cross-linking and cytotoxic effects. The regimen aims to synergistically boost immune response, suppress tumor angiogenesis, and directly kill tumor cells. It is delivered intravenously, with AK104 having limited Fc-mediated cytotoxicity, and frequently includes maintenance therapy with AK104 ± bevacizumab[1][4][6].
- Brand names
- Avastin
- Other names
- cadonilimab + bevacizumab + paclitaxel + cisplatin or carboplatin
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)DNATUBB (Tubulin (alpha and beta subunits))CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on AK104 + bevacizumab + paclitaxel + cisplatin or carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AK104 + bevacizumab + paclitaxel + cisplatin or carboplatin.